Clinical trial
A Randomized, Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib, and Dexamethasone (RVD) to High-Dose Treatment With Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients Up to 65 Years of Age
NCT01208662 is registered in ClinicalTrials.gov with Paul Richardson, MD as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib, and Dexamethasone (RVD) to High-Dose Treatment With Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients Up to 65 Years of Age
- Lead sponsor
- Paul Richardson, MD
- Phase
- Phase 3
- Overall status
- Active, not recruiting
- Start date
- September 30, 2010
- Completion date
- December 31, 2026
- Enrollment
- 729 (actual)
- Sites
- 46
Conditions
As the registry lists them; a condition with its own page is linked.